Korro Bio presents KRRO-121 development plan, targets interim data in second half of 2027
KRRO•Korro Bio expects to begin dosing urea cycle disorder patients with KRRO-121 in the first half of 2027 and expects interim data in the second half. The company plans a KRRO-111 regulatory submission in the first half of 2027 and says its cash runway extends into the second half of 2028.
1. Development milestones
Korro Bio expects to begin dosing urea cycle disorder patients with KRRO-121 in the first half of 2027, with interim data expected in the second half. The company plans to submit KRRO-111 for regulatory review in the first half of 2027 and says its cash runway extends into the second half of 2028.
